Protalix BioTherapeutics (PLX) Gross Profit (2016 - 2025)
Historic Gross Profit for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $9.5 million.
- Protalix BioTherapeutics' Gross Profit fell 59.47% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year increase of 11724.26%. This contributed to the annual value of $29.1 million for FY2024, which is 3159.58% down from last year.
- Per Protalix BioTherapeutics' latest filing, its Gross Profit stood at $9.5 million for Q3 2025, which was down 59.47% from $9.8 million recorded in Q2 2025.
- Protalix BioTherapeutics' Gross Profit's 5-year high stood at $28.9 million during Q2 2023, with a 5-year trough of $1.1 million in Q1 2024.
- In the last 5 years, Protalix BioTherapeutics' Gross Profit had a median value of $6.5 million in 2023 and averaged $7.5 million.
- Examining YoY changes over the last 5 years, Protalix BioTherapeutics' Gross Profit showed a top increase of 77926.38% in 2024 and a maximum decrease of 8610.99% in 2024.
- Quarter analysis of 5 years shows Protalix BioTherapeutics' Gross Profit stood at $5.4 million in 2021, then rose by 15.16% to $6.2 million in 2022, then plummeted by 73.79% to $1.6 million in 2023, then surged by 779.26% to $14.3 million in 2024, then tumbled by 33.53% to $9.5 million in 2025.
- Its Gross Profit was $9.5 million in Q3 2025, compared to $9.8 million in Q2 2025 and $1.9 million in Q1 2025.